PWMA
PTGX icon

Pension & Wealth Management Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Pension & Wealth Management Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20
Closed -$2.11K – 571
2026
Q1 		$2.11K Buy
+20
New +$1.77K ﹤0.01% 464

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Pension & Wealth Management Advisors's PTGX Position: Q2 2026 in Review

Pension & Wealth Management Advisors sold out of Protagonist Therapeutics (PTGX) in Q2 2026, closing a stake of 20 shares — an estimated $2.11K sold.

Pension & Wealth Management Advisors first reported a position in PTGX in Q1 2026 and held it in 1 quarter. The position peaked at $2.11K in Q1 2026. 316 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Pension & Wealth Management Advisors reported no remaining Protagonist Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Pension & Wealth Management Advisors sold 20 Protagonist Therapeutics shares in Q2 2026, an estimated $2.11K.
  • Pension & Wealth Management Advisors first reported a position in Protagonist Therapeutics in Q1 2026 and held it in 1 quarter.
  • Pension & Wealth Management Advisors's Protagonist Therapeutics position peaked at $2.11K in Q1 2026.
  • 316 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Pension & Wealth Management Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.